BAP, the California-based drugmaker behind the opioid crisis, is preparing for a possible opioid crisis in Florida, which it has been trying to stem since March.
The company will begin administering the drug, called buprenorphine, in a limited number of Florida counties on Monday.
The FDA is expected to approve buprevorphine in about a week, and the drug is expected by the end of July, according to the company’s CEO, David D’Angelo.
Florida’s opioid crisis has been exacerbated by a shortage of naloxone, a drug that can reverse the effects of opioid overdoses.
Florida has more than 11,000 opioid deaths a year, according a recent report from the Centers for Disease Control and Prevention.
The state has a population of about 12.6 million people, according the state’s most recent state data.
“Our plan is to get this drug in as many places as we can, to the extent that we can,” D’angelo told the Associated Press.
D’Alvon said the company is prepared for an increase in overdoses from the crisis.
“We’re going to be prepared for any increase in use, any increase of opioid use,” he said.
Florida is one of three states in the country that has not yet received bupregrenorphines from the FDA, but the drug will likely be administered in the state for the first time in the next week, according D’Langelo.
The Florida Department of Health told ABC News that it expects the buprelaxine injection site to be open for at least two weeks.
The site is being set up in Sanford, the state capital, according To the AP, D’ Avilo told the AP that he hopes to begin administering buprestorphine within 24 hours, as soon as possible.
The bupresorphine injectable is not approved for use in people who are already addicted to opiates.
D Avila said the FDA was reluctant to grant bupprescription because the drug has not been approved by the Food and Drug Administration.
The agency said in May that the drug would be approved by early July.
The Drug Enforcement Administration approved bupristorphine for use to treat opioid addiction in May, but has not approved it for use for people with HIV or hepatitis C. That decision was a blow to many advocates who were hoping that the agency would approve the drug for treatment for HIV and hepatitis C, as well as people who had not previously been diagnosed with either disease.
The drug is available through health clinics and clinics that offer treatment services to people who have been diagnosed HIV or with hepatitis C and cannot afford to buy it online.
In a letter to the FDA last week, the Drug Enforcement Agency urged that the approval of buprazolam be delayed until the agency can “fully assess the medical, public health, and economic impacts of this new treatment option.”
The letter also urged that other opioids be taken off the market to allow for more time to review their effects.
“It’s important that you not make this drug available in the midst of the opioid epidemic and continue to delay approval of the product that you have so desperately needed to help patients,” the DEA wrote.
The DEA also said that “a more appropriate time for the agency to make a decision regarding the FDA approval of this drug is during the period that the FDA has not received any additional information from the manufacturer regarding the drug’s safety, efficacy, and abuse potential.”
The DEA letter said it was “important that you continue to monitor the development of bupatrol, as you continue evaluating the FDA’s decision regarding approval of its bupraloxaban.”